NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment<
16 Sep 2025

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

VarmX shareholders to receive initial $117m upfront and further potential milestone payments up to $2.1bn.
Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors<
09 Sep 2025

Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

Expect to share preliminary data from the trial by early to mid-2026
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need<
05 Sep 2025

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Lorundrostat demonstrated significant and clinically meaningful blood pressure reductions across all participant subgroups, with a favorable safety and tolerability profile
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares<
04 Sep 2025

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Proceeds will support lorundrostat clinical development, manufacturing, pre-commercialization, and expansion in hypertension and related diseases
VarmX receives FDA Fast Track Designation for lead asset VMX-C001<
03 Sep 2025

VarmX receives FDA Fast Track Designation for lead asset VMX-C001

Fast Track status aims to expedite review of drugs addressing serious conditions and unmet medical needs
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock<
02 Sep 2025

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Mineralys intends to use the net proceeds from the proposed offering to fund clinical development of lorundrostat
Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency<
23 Jul 2025

Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency

EMA has now validated the MAA file and it is under review by the Committee for Medicinal Products for Human Use (CHMP).
Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation<
23 Jul 2025

Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation

Novel antibody, potravitug, demonstrates high neutralization of all BKPyV serotypes with potential to transform treatment for kidney transplant recipients with BKPyV infection
Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial<
17 Jul 2025

Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial

Preliminary clinical data from Xabg, Xeltis' coronary artery bypass conduit (CABG), demonstrating positive safety and patency
Minoryx receives a EUR 26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseases<
17 Jul 2025

Minoryx receives a EUR 26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseases

The grant was given as part of the pan-European project “Important Project of Common European Interest (‘IPCEI') Med4Cure”

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.